Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Summary of Company's Financial Data for Development and Commercialization of Pharmaceutical Products Segment

The following table summarizes the Company’s financial data for its development and commercialization of pharmaceutical products segment:

	Year Ended December 31,
	2024			2023
Net product sales	$	10,249,415		$	5,180,630
Less:
Cost of goods sold		(356,531	)		(201,879	)
Eversana profit sharing		(8,733,347	)		(4,401,590	)
Employee expenses		(2,481,056	)		(3,188,601	)
Professional fees		(2,059,591	)		(2,553,662	)
Stock-based compensation		(773,121	)		(1,128,109	)
Sales and marketing expenses		(750,272	)		(659,535	)
Other operating expenses(1)		(299,634	)		(478,145	)
Interest income		353,313			138,596
Interest expense (non-cash)		(501,370	)		(500,000	)
Total segment costs loss and net loss	$	(5,352,194	)	$	(7,792,295	)

________________

(1) Includes ongoing product development costs, occupancy costs (including rent and utilities), administrative costs, travel and business taxes.